Tums Sales Gain 6% To $43 Mil. In U.S. Third Quarter; Tagamet HB Down
This article was originally published in The Tan Sheet
Executive Summary
Third quarter sales for SmithKline Beecham's Tums rose 6% to $43 mil. in the U.S., and the antacid brand "solidified" its number two position in the stomach remedy market, the company said Oct. 20. Worldwide Tums sales were up 4%.